Full Press Release Details
Melbourne (Australia) | 23 April 2024
Telix today announces five oral abstract presentations featuring the Company’s late-stage theranostic programs at the 54 th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM ASM 2024), being held in Christchurch (New Zealand) from 26-28 April 2024.
Presentations cover: TLX591 ( 177 Lu rosopatamab tetraxetan), Telix’s lead investigational radio antibody-drug conjugate (rADC) therapy for prostate cancer; Illuccix® ( 68 Ga-PSMA-11), Telix’s approved PET imaging agent for prostate cancer; and TLX250-CDx ( 89 Zr-DFO-girentuximab, Zircaix® 1 ), Telix’s investigational PET imaging agent for kidney cancer.
In addition, we are pleased to host a Breakfast Session on the latest innovations in theranostics and once again support the Nurses Workshop in collaboration with the Prostate Cancer Foundation of Australia (PCFA), NeuroEndocrine Cancer Australia (NECA) and the Peter MacCallum Cancer Centre in Melbourne.
Come and meet with us in person at booths 29 and 30 to discuss Telix’s extensive late-stage theranostic pipeline in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning, our associated medical devices and artificial intelligence (AI), along with opportunities for collaboration.
Details of ANZSNM ASM 2024 abstract presentations related to Telix programs are listed below and the full congress program can be accessed here .
Title: Lutetium-177 labelled anti-PSMA monoclonal antibody (TLX591, 177 Lu rosopatamab tetraxetan) therapy for metastatic prostate cancer: real-world data on treatment toxicity and outcomes
Presenter: Hanh Nguyen, Fiona Stanley Hospital (Perth, Western Australia)
Date and Time: Friday 26 April, 2024 | 5:00 pm – 5:15 pm (NZT)
Session: Therapy Session
Format: Oral Presentation
Location: Te Pae Auditorium
Title: Characterising prostate cancer risk with 68 Ga‑PSMA-11 (Illuccix®) PET/CT imaging and AI
Presenter: Simon Wail, Telix Pharmaceuticals
Date and Time: Saturday 27 April, 2024 | 12:15 pm – 12:30 pm (NZT)
Session: Physics Session
Format: Oral Presentation
Location: Dobson 4
Title: Successful use of 68 Ga-PSMA-11 for prostate cancer imaging at an Australian imaging centre
Presenter: Alexis Dalagiorgos, Jones Radiology (Adelaide, South Australia)
Date and Time: Saturday 27 April, 2024 | 2:30 pm – 2:45 pm (NZT)
Session: Oncology Session
Format: Oral Presentation
Location: Dobson 1
Title: Safety, tolerability, and dosimetry of TLX591 with best standard of care in patients with PSMA-expressing metastatic castration resistant prostate cancer (ProstACT SELECT)
Presenter: Nat Lenzo, Nuclear Oncologist and General Internal Medicine Physician (Perth, Western Australia)
Date and Time: Saturday 27 April, 2024 | 2:45 pm – 3:00 pm (NZT)
Session: Oncology Session
Format: Oral Presentation
Location: Dobson 1
ClinicalTrials.gov ID: NCT04786847
Title: 89 Zr-DFO-girentuximab (TLX250-CDx): Evaluation of radiation dosimetry, safety, and optimal imaging parameters in Chinese patients with indeterminate renal masses (ZIRDOSE-CP)
Presenter: Shams Arifeen, Telix
Date and Time: Sunday 28 April, 2024 | 2:15 pm – 2.30 pm (NZT)
Session: Across the Motu/Country Session
Format: Oral Presentation
Location: Te Pae Auditorium
ClinicalTrials.gov ID: NCT05861778
Breakfast Session and Nurses Workshop
Telix Hosted Breakfast
Location: Dobson 4
Date and Time: Saturday 27 April, 2024 | 7:00 am – 8:15 am (NZT)
Topics and Presenters:
Breakfast attendance is free! Register via the main conference website:
Nurses Workshop, Providing Optimal Care in Radiotheranostics
Location: Dobson 3
Date and Time: Saturday 27 April, 2024 | 1:30 pm – 3:30 pm (NZT)
Topics and Presenters:
Illuccix® has been approved by the U.S. Food and Drug Administration (FDA), by the Australian Therapeutic Goods Administration (TGA), and by Health Canada. No other Telix product has received a marketing authorisation in any jurisdiction. Zircaix® brand name is subject to final regulatory approval.